Feature Channels: Clinical Trials

Filters close
Released: 16-Mar-2023 2:30 PM EDT
New Trials Show Promising, Minimally Invasive Procedure to Treat Resistant Hypertension
Ochsner Health

A recent study published in JAMA demonstrates the effectiveness of a procedure done under the skin, similar to placing a stent, to treat uncontrolled hypertension, or blood pressure that cannot be controlled despite the use of blood pressure control drugs and agents.

Newswise:Video Embedded clinical-trial-investigating-innovative-way-to-control-type-2-diabetes
VIDEO
Released: 16-Mar-2023 10:05 AM EDT
Clinical trial investigating innovative way to control Type 2 diabetes
Keck Medicine of USC

Keck Medicine of USC has launched a Phase 2 clinical trial investigating the effectiveness of a new outpatient, nonsurgical endoscopic procedure in stabilizing blood glucose levels for patients.

14-Mar-2023 12:00 PM EDT
Targeting menin induces responses in acute leukemias with KMT2A rearrangements or NPM1 mutations
University of Texas MD Anderson Cancer Center

Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with revumenib, previously known as SNDX-5613, yielded encouraging responses for advanced acute leukemias with KMT2A rearrangements or mutant NPM1. Findings from the Phase I AUGMENT-101 trial were published today in Nature.

Newswise:Video Embedded new-focused-ultrasound-effective-for-treating-parkinson-s-movement-disorders
VIDEO
Released: 14-Mar-2023 3:00 PM EDT
New Focused Ultrasound Effective for treating Parkinson’s, Movement Disorders
University of North Carolina School of Medicine

In a study published in the New England Journal of Medicine co-authored by Vibhor Krishna, MD, associate professor of neurosurgery at the UNC School of Medicine, researchers show that a new focused ultrasound treatment improved dyskinesia and motor impairment in patients with Parkinson’s disease.

Released: 14-Mar-2023 7:00 AM EDT
Pesquisa em fase inicial da Mayo Clinic encontra na terapia com células-tronco uma perspectiva para fístula perianal em pacientes com doença de Crohn
Mayo Clinic

Um plugue absorvível entregou terapia com células-tronco com poucos efeitos colaterais em pacientes com fístulas perianais de trato único, segundo descoberta de pesquisadores da Mayo Clinic.

Released: 14-Mar-2023 7:00 AM EDT
Las primeras investigaciones en Mayo Clinic encuentran esperanza en la terapia con células madres para las fístulas perianales en pacientes con la enfermedad de Crohn
Mayo Clinic

Los investigadores de Mayo Clinic descubrieron que un tapón soluble administró terapia con células madre ocasionando pocos efectos secundarios en pacientes con fístulas perianales de un solo trayecto.

Released: 14-Mar-2023 7:00 AM EDT
بحث في المراحل المبكرة لمايو كلينك يجد أملًا في الخلايا الجذعية لعلاج الناسور الشرجي لدى المرضى المصابين بداء كْرون
Mayo Clinic

توصّل باحثو مايو كلينك إلى إمكانية العلاج بالخلايا الجذعية عبر سدادة قابلة للذوبان لديها آثارٌ جانبية قليلة على المرضى المصابين بالناسور الشرجي أحادي السبيل. النواسير الشرجية هي ممرات مؤلمة بين الأمعاء والجلد، ولا تُشفى عادةً بالرعاية الطبية أو الجراحية القياسية. إن المصابين بداء كْرون أو غيره من حالات التهاب الأمعاء هم الأكثر عرضة لخطر الإصابة بهذه الحالة المرضية.

Newswise: Hackensack University Medical Center Interventional Cardiologists Are Leaders in Multicenter Clinical Trial of Percutaneous Heart Pump Added to Cardiac Catheterization
Released: 13-Mar-2023 4:20 PM EDT
Hackensack University Medical Center Interventional Cardiologists Are Leaders in Multicenter Clinical Trial of Percutaneous Heart Pump Added to Cardiac Catheterization
Hackensack Meridian Health

Hackensack University Medical Center interventional cardiologists are regional leaders in the multicenter national PROTECT IV clinical trial, which is evaluating the effectiveness of a novel treatment for high-risk patients with complex heart disease and reduced heart function who require cardiac catheterization.

Newswise: New Class of Drugs Could Prevent Resistant COVID-19 Variants
Released: 10-Mar-2023 6:00 PM EST
New Class of Drugs Could Prevent Resistant COVID-19 Variants
Yale Cancer Center/Smilow Cancer Hospital

The constant evolution of new COVID-19 variants makes it critical for clinicians to have multiple therapies in their arsenal for treating drug-resistant infections. Researchers have now discovered that a new class of oral drugs that acts directly on human cells can inhibit a diverse range of pathogenic SARS-CoV-2 strains. In their newly published study, the team found a novel mechanism through which the gene that expresses angiotensin converting enzyme-2 (ACE-2)—the cellular receptor to which SARS-CoV-2 binds so that it can enter and infect the cell—is turned on.

Released: 9-Mar-2023 11:15 AM EST
CBD oil doesn't reduce pain after common treatment for urinary stones
Wolters Kluwer Health: Lippincott

Treatment with an FDA-approved cannabidiol (CBD) oil product does not lower pain scores after surgical treatment and stent placement for patients with urinary stones, reports a clinical trial in the April issue of The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Newswise: Can hormone replacement therapy protect the heart and brain after menopause?
Released: 9-Mar-2023 10:05 AM EST
Can hormone replacement therapy protect the heart and brain after menopause?
Keck Medicine of USC

Keck Medicine of USC has launched a clinical trial to study the effect of a novel hormone replacement therapy on postmenopausal cardiovascular disease and cognitive decline.

Newswise: PCORI Awards Researchers $10.2 Million to Study Individualized Model of Hemodialysis
Released: 9-Mar-2023 10:05 AM EST
PCORI Awards Researchers $10.2 Million to Study Individualized Model of Hemodialysis
Wake Forest University School of Medicine

The Patient-Centered Outcomes Research Institute (PCORI) recently awarded researchers at Wake Forest University School of Medicine $10.2 million to study the effectiveness of an individualized model of hemodialysis, a procedure in which the blood is cleaned by a dialysis machine. The project is a collaboration between the School of Medicine, the Renal Research Institute and other health care systems across the country.

Newswise: Study explores how community engagement can help improve clinical trial diversity
Released: 9-Mar-2023 9:00 AM EST
Study explores how community engagement can help improve clinical trial diversity
Ohio State University Wexner Medical Center

In an effort to improve clinical trial diversity, researchers at The Ohio State University Wexner Medical Center and College of Medicine led a study to create solutions to barriers of access, awareness, discrimination and racism and workforce diversity.

Released: 8-Mar-2023 2:35 PM EST
University Hospitals chosen to participate in a groundbreaking initiative to accelerate uptake of practice-changing evidence in health care
University Hospitals Cleveland Medical Center

Announcement that the Patient-Centered Outcomes Research Institute (PCORI) tapped University Hospitals (UH) as one of 42 health systems nationwide to carry out a pioneering initiative to accelerate the implementation of practice-changing research results in clinical care to improve patients’ outcomes.

Newswise: Cedars-Sinai Surgeon-in-Chief Selected for Expanded Academic Leadership Post
Released: 8-Mar-2023 1:55 PM EST
Cedars-Sinai Surgeon-in-Chief Selected for Expanded Academic Leadership Post
Cedars-Sinai

Cedars-Sinai has selected Bruce L. Gewertz, MD, the medical center’s surgeon-in-chief, to be the vice dean of Clinical System Development and Faculty Affairs.

Released: 8-Mar-2023 12:40 PM EST
New Study: Abatacept Therapy Offers Promising Results Treating Juvenile Dermatomyositis
George Washington University

Juvenile dermatomyositis, a rare but often severe and chronic systemic autoimmune disease, includes a large number of patients who are treatment resistant, requiring long term immunosuppressive therapy. A small open-label study published in Arthritis and Rheumatology shows promise using a targeted biologic therapy called abatacept to treat such patients.

Released: 8-Mar-2023 9:00 AM EST
Seeking leukemia’s Achilles heel
American Society for Biochemistry and Molecular Biology (ASBMB)

A team of researchers has discovered a potential therapeutic that can synergize with existing drugs to more effectively kill certain leukemia cells. The authors published their results on Jan. 19 in the journal Molecular & Cellular Proteomics.

Released: 7-Mar-2023 10:05 AM EST
Cornell-developed anti-TB compound headed to trials
Cornell University

A novel compound that has the potential to starve the bacteria that causes tuberculosis – the world’s leading infectious killer after SARS-CoV2 – is entering human clinical trials.

Released: 6-Mar-2023 5:50 PM EST
Denovo Biopharma Creates Innovative Gene Registry Program to Support the First Precision Medicine for Treatment Resistant Depression
Denovo Biopharma LLC

Denovo Biopharma LLC ("Denovo"), a pioneer in applying precision medicine to the development of innovative therapies, set up a gene registry web portal and invites people who suffer from treatment-resistant depression (TRD) to visit www.iMatchDepression.com to help identify whether they or someone they know may be eligible to participate in a biomarker-guided global Phase 2b clinical trial (the "ENLIGHTEN" study).

Newswise: Temperature-stable TB vaccine safe, prompts immune response in NIH-supported study
Released: 6-Mar-2023 2:05 PM EST
Temperature-stable TB vaccine safe, prompts immune response in NIH-supported study
NIH, National Institute of Allergy and Infectious Diseases (NIAID)

A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system.

Newswise: High-Dose Anticoagulation Can Reduce Intubations and Improve Survival for Hospitalized COVID-19 Patients
Released: 6-Mar-2023 12:00 PM EST
High-Dose Anticoagulation Can Reduce Intubations and Improve Survival for Hospitalized COVID-19 Patients
Mount Sinai Health System

High-dose anticoagulation can reduce deaths by 30 percent and intubations by 25 percent in hospitalized COVID-19 patients who are not critically ill when compared to the standard treatment, which is low-dose anticoagulation.

Newswise: Support Secured for Yale Cancer Center Consortium to Advance Equity in Early-Phase Clinical Trials
Released: 6-Mar-2023 10:00 AM EST
Support Secured for Yale Cancer Center Consortium to Advance Equity in Early-Phase Clinical Trials
Yale Cancer Center/Smilow Cancer Hospital

The intent of the new Consortium is to help increase access to early phase cancer clinical trials for patients who would otherwise not have the ability to be treated with novel investigational therapeutic interventions.

Released: 3-Mar-2023 2:15 PM EST
AI used to predict future flares of ulcerative colitis activity
University of Birmingham

Ulcerative colitis assessment could be improved after new research shows that an artificial intelligence model could predict flare-ups and complications after reading biopsies.

   
Released: 2-Mar-2023 2:35 PM EST
Early Mayo Clinic research finds hope in stem cell therapy for perianal fistulas in patients with Crohn’s disease
Mayo Clinic

A dissolvable plug delivered stem cell therapy with few side effects in patients with single tract perianal fistulas, Mayo Clinic researchers discovered. Perianal fistulas are painful tunnels between the intestine and the skin that often do not go away with standard medical or surgical care.

Released: 1-Mar-2023 5:10 PM EST
Pharma Industry Consortium Completes Brain Wave Study of Ketamine Effects on Healthy Volunteers
Cognision®

The ERP Biomarker Qualification Consortium announced today the successful completion of a pharma industry-sponsored study to measure the electrophysiologic effects of ketamine on healthy brain function.

   
1-Mar-2023 3:45 PM EST
Neoadjuvant Pembrolizumab Administered Before Surgery Improves Outcomes of Melanoma Patients
Moffitt Cancer Center

A team of researchers from institutions across the United States, including Moffitt Cancer Center, launched a phase 2 clinical trial evaluating a new treatment option for this patient population. Their results, published in The New England Journal of Medicine, show that treating resectable stage 3 and 4 melanoma patients with the immunotherapy drug pembrolizumab both before and after surgery greatly improves outcomes when compared to pembrolizumab given only after surgery.

Released: 28-Feb-2023 12:45 PM EST
Clinical trial for patients with swallowing difficulties after cancer treatment
UC Davis Health (Defunct)

UC Davis Health researchers have begun a new stem cell clinical trial to treat patients with swallowing problems. The study takes stem cells and injects them into the patient’s tongue.

Released: 27-Feb-2023 5:05 PM EST
Taking Aim at Prostate Cancer
University of New Mexico Comprehensive Cancer Center

The UNM Cancer Center will be one of a few sites in the country participating in a clinical trial to expand the application of theranostic treatment to patients with prostate cancer. This type of treatment is currently used at the cancer center for neuroendocrine tumors. The treatment is a two-part process that first injects the molecule attached to a gallium-68 radioactive isotope that can be imaged to illuminate the cancer cells, which makes them easier to see under Positron Emission Tomography, or PET scans.

Newswise: Cedars-Sinai Welcomes Biomedical Data Science Expert
Released: 27-Feb-2023 12:50 PM EST
Cedars-Sinai Welcomes Biomedical Data Science Expert
Cedars-Sinai

Nicholas Tatonetti, PhD, an expert in biomedical data science, has joined Cedars-Sinai as the vice chair of Computational Biomedicine and associate director for Computational Oncology at Cedars-Sinai Cancer.

Newswise: Markey Cancer Center study shows potential for new radiopharmaceutical cancer treatment
Released: 24-Feb-2023 1:25 PM EST
Markey Cancer Center study shows potential for new radiopharmaceutical cancer treatment
University of Kentucky

A recent University of Kentucky Markey Cancer Center study suggests a new radiopharmaceutical compound may be a viable treatment option for patients with advanced cervical cancer.

Newswise:Video Embedded ku-cancer-center-uses-art-to-reach-underserved-communities
VIDEO
Released: 23-Feb-2023 4:35 PM EST
KU Cancer Center uses art to reach underserved communities
University of Kansas Cancer Center

The mural, designed in collaboration with members of organizations in the surrounding urban community, is one part of the The University of Kansas Cancer Center’s broader campaign to increase the participation of minority and underserved populations in clinical trials.

Released: 23-Feb-2023 2:55 PM EST
Phase 3 Trial Finds Oral Empagliflozin Provided Safe Glycemic Control in Children with Type 2 Diabetes
Joslin Diabetes Center

Researchers recently completed a phase 3 clinical trial that assessed the efficacy and safety of two different classes of oral agents for the treatment of type 2 diabetes in young people aged 10-17 years.

Newswise:Video Embedded parkinson-s-disease-patients-experience-significant-reduction-in-symptoms-with-non-surgical-focused-ultrasound-treatment
VIDEO
21-Feb-2023 2:00 PM EST
Parkinson’s Disease Patients Experience Significant Reduction in Symptoms with Non-Surgical Focused Ultrasound Treatment
University of Maryland School of Medicine

Patients with Parkinson’s disease achieved a significant improvement in their tremors, mobility, and other physical symptoms after having a minimally invasive procedure involving focused ultrasound, according to a new study today published in the New England Journal of Medicine.

Newswise: U.S. Study of Intravenous Mistletoe Extract to Treat Advanced Cancer
Released: 22-Feb-2023 10:00 AM EST
U.S. Study of Intravenous Mistletoe Extract to Treat Advanced Cancer
Johns Hopkins Medicine

Researchers at the Johns Hopkins Kimmel Cancer Center completed what is believed to be the first phase I trial of intravenous Helixor M in the U.S. aimed at determining dosing for subsequent clinical trials and to evaluate safety.

Newswise: Lo Que Debes Saber Acerca del Medicamento Recientemente Aprobado Contra el Alzheimer
Released: 21-Feb-2023 1:25 PM EST
Lo Que Debes Saber Acerca del Medicamento Recientemente Aprobado Contra el Alzheimer
Cedars-Sinai

Leqembi, Recientemente Aprobado por la FDA, Muestra un Beneficio Potencial para los Pacientes con Enfermedad en Etapa Temprana, pero la Disponibilidad Llevará tiempo, Comenta Experta de Cedars-Sinai

Released: 21-Feb-2023 8:00 AM EST
O que é considerado clinicamente significativo para desacelerar a progressão do Alzheimer?
Mayo Clinic

Um grupo de trabalho de especialistas reformulou o que é considerado clinicamente significativo para desacelerar a progressão da doença de Alzheimer durante ensaios clínicos, incluindo o impacto do tratamento ao longo do tempo e a necessidade de terapias combinadas.

Released: 21-Feb-2023 8:00 AM EST
¿Qué es importante a nivel clínico para retrasar el avance de la enfermedad de Alzheimer?
Mayo Clinic

Un grupo de trabajo de expertos ha replanteado qué es importante a nivel clínico para retrasar el avance de la enfermedad de Alzheimer durante los ensayos clínicos, incluidas la repercusión del tratamiento a lo largo del tiempo y la necesidad de terapias combinadas.

Newswise: A Tool to Prevent Deaths Due to Female Underrepresentation in Clinical Trials
13-Feb-2023 12:20 PM EST
A Tool to Prevent Deaths Due to Female Underrepresentation in Clinical Trials
Biophysical Society

ROCKVILLE, MD – Women are often underrepresented in cardiac clinical trials—yet they are at least at equally high risk of death due to cardiovascular disease, and at higher risk of developing drug-induced heart complications compared to men. Clinical trials of medicines generally rely on electrocardiograms (EKG) to measure a patient’s heart’s response to a medicine and determine its safety, yet males and females have a number of differences in their heart physiology that are reflected in consistent variations in their EKGs.

   
16-Feb-2023 7:15 PM EST
Immunotherapy After Surgery Provides Significant, Durable Benefit for High-Risk Bladder Patients
Mount Sinai Health System

Immunotherapy after surgery increased bladder cancer patients’ chance of staying cancer-free compared to patients who received a placebo, according to clinical trial results shared in a late-breaking oral presentation at the American Society of Clinical Oncology (ASCO) 2023 Genitourinary Cancers Symposium in February.

Newswise: FAU, Delray Medical Center, Insightec Team Up on Groundbreaking Alzheimer’s Study
Released: 17-Feb-2023 8:30 AM EST
FAU, Delray Medical Center, Insightec Team Up on Groundbreaking Alzheimer’s Study
Florida Atlantic University

Delray Medical Center is the first hospital in Florida to treat an Alzheimer’s disease patient using non-invasive focused ultrasound technology as part of a groundbreaking study being conducted in collaboration with FAU’s Institute for Human Health and Disease Intervention (I-Health). In the FDA-approved clinical trial, focused ultrasound technology is used to disrupt the blood-brain barrier in participating Alzheimer’s patients.

Newswise:Video Embedded lapd-sergeant-didn-t-walk-alone
VIDEO
Released: 15-Feb-2023 12:05 PM EST
LAPD Sergeant Didn’t Walk Alone
Cedars-Sinai

Every day for six weeks, Neil Wank, a 26-year Los Angeles Police Department veteran who in December was diagnosed with an aggressive type of brain cancer called glioblastoma, was escorted down the long hallway leading to the Cedars-Sinai Cancer radiation therapy facility by his wife, Nikki, and 10 to 20 of his fellow officers.

Newswise: Jaime Merchán, M.D., Named a Translational and Clinical Oncology Research Program Co-Leader
Released: 15-Feb-2023 8:00 AM EST
Jaime Merchán, M.D., Named a Translational and Clinical Oncology Research Program Co-Leader
Sylvester Comprehensive Cancer Center

Jaime Merchán, M.D., is the new Translational and Clinical Oncology Research Program co-leader at Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System.

Newswise: Lung cancer study finds new target for treatment resistance after EGFR inhibitors
10-Feb-2023 5:00 PM EST
Lung cancer study finds new target for treatment resistance after EGFR inhibitors
University of Texas MD Anderson Cancer Center

Researchers at The University of Texas MD Anderson Cancer Center have identified CD70 as being highly expressed on drug-resistant cancer cells in EGFR-mutant non-small cell lung cancer (NSCLC), highlighting a novel therapeutic target that could be used to eliminate resistant cells remaining after treatment with commonly used EGFR tyrosine kinase inhibitors (TKIs). The study published today in Cancer Cell.

   
Newswise: 2023 Kappa Delta Ann Doner Vaughn Award Presented to Michelle Ghert, MD, FRCSC, and the PARITY Investigators for First-Ever International Multi-Center Randomized Controlled Trial in Orthopaedic Oncology
Released: 10-Feb-2023 2:55 PM EST
2023 Kappa Delta Ann Doner Vaughn Award Presented to Michelle Ghert, MD, FRCSC, and the PARITY Investigators for First-Ever International Multi-Center Randomized Controlled Trial in Orthopaedic Oncology
American Academy of Orthopaedic Surgeons (AAOS)

The 2023 Kappa Delta Ann Doner Vaughn Award was given to Michelle Ghert, MD, FRCSC, on behalf of the Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) investigators for their research on the prevention of surgical site infections (SSIs) through antibiotic prophylaxis following oncologic reconstruction surgery for bone tumors.

Newswise: Kappa Delta Elizabeth Winston Lanier Award Presented to Major Extremity Trauma Research Consortium for Development of Largest Orthopaedic Trauma Research Endeavor
Released: 10-Feb-2023 2:55 PM EST
Kappa Delta Elizabeth Winston Lanier Award Presented to Major Extremity Trauma Research Consortium for Development of Largest Orthopaedic Trauma Research Endeavor
American Academy of Orthopaedic Surgeons (AAOS)

The 2023 Kappa Delta Elizabeth Winston Lanier Award was presented to the Major Extremity Trauma Research Consortium (METRC) for its multi-disciplinary research platform addressing the challenging issues related to the evaluation, treatment and recovery after severe extremity trauma.

Released: 10-Feb-2023 1:20 PM EST
Falling PSA levels predict longer survival in prostate cancer patients at high risk of metastases
Wolters Kluwer Health: Lippincott

Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic castration-resistant prostate cancer (nmCRPC), reports The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

7-Feb-2023 3:05 PM EST
New Formulation of FDA-Approved Drug Shows Encouraging Results for Treating a Common Itch Condition
Mount Sinai Health System

Notalgia paresthetica is a common and underdiagnosed condition characterized by a persistent itch in the upper back. To date, there are no FDA-approved treatments specifically targeting this disorder. But a new study, published in the NEJM, suggests that patients with the disorder could potentially get relief with oral difelikefalin.

Newswise: Single-dose treatment reduces risk of COVID-19 hospitalization by half for high-risk patients in a largely vaccinated population
8-Feb-2023 12:20 PM EST
Single-dose treatment reduces risk of COVID-19 hospitalization by half for high-risk patients in a largely vaccinated population
University Health Network (UHN)

A single-dose of the antiviral drug peginterferon lambda reduced by half the risk of hospitalization or a visit to the Emergency Department due to COVID-19, according to a study published today in the New England Journal of Medicine.

Newswise: Cleveland Clinic Announces Next Step in Preventive Breast Cancer Vaccine Study
8-Feb-2023 7:05 AM EST
Cleveland Clinic Announces Next Step in Preventive Breast Cancer Vaccine Study
Cleveland Clinic

Cleveland Clinic researchers have launched the next step in their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.



close
2.53468